# National Research Corporation (NRC) Stock Analysis: Balancing Robust ROE and Dividend Yield Amidst Revenue Challenges

- Link: https://www.directorstalkinterviews.com/national-research-corporation-nrc-stock-analysis-balancing-robust-roe-and-dividend-yield-amidst-revenue-challenges/4121241661
- Published: 2026-02-26T11:14:40+00:00
- Author: Madison Wilson

National Research Corporation (NRC), trading on the U.S. exchange in the healthcare
sector, specializes in health information services, providing an essential suite
of analytics and insights for healthcare organizations. With a market capitalization
of $292.96 million, NRC is a notable player within its industry, yet it finds itself
at a crossroads as it navigates a challenging revenue landscape and fluctuating 
stock performance.

Currently priced at $12.93, NRC’s stock has experienced significant volatility over
the past year, swinging between $10.13 and $22.48. This wide 52-week range hints
at investor uncertainty, likely driven by its recent revenue contraction of 4.60%.
Despite these challenges, the company boasts a commendable Return on Equity (ROE)
of 51.24%, indicating a highly effective use of shareholders’ equity to generate
profit.

Interestingly, NRC’s price movement also reflects broader market sentiment, with
its 50-day moving average at $17.90 and the 200-day moving average at $15.51—a sign
that recent trading has been somewhat bearish. The Relative Strength Index (RSI)
at 59.56 suggests the stock is approaching overbought territory, which can often
precede a price correction.

A standout feature of NRC’s financial profile is its dividend yield of 4.33%, coupled
with a concerning payout ratio of 104.00%. This suggests that the company is distributing
more in dividends than it earns, a situation that may not be sustainable in the 
long term without an uptick in earnings or a strategic shift in dividend policy.
Investors drawn to NRC for income should weigh this risk carefully against the potential
for future yield adjustments.

From a valuation perspective, the absence of metrics such as P/E ratio, PEG ratio,
and EV/EBITDA could imply challenges in traditional valuation assessments, possibly
due to the company’s current fiscal complexities or industry-specific factors not
captured in standard metrics.

Despite the lack of explicit analyst ratings or target prices, NRC’s performance
and strategic endeavors in healthcare analytics and reputation management remain
integral to healthcare providers seeking to enhance patient and employee experiences.
The company’s innovative solutions, such as the Huey AI for healthcare experience
management, position it as a forward-thinking enterprise in an evolving sector.

For individual investors, the investment case for NRC hinges on a nuanced understanding
of its revenue dynamics, profitability metrics, and strategic growth initiatives.
While the robust ROE and attractive dividend yield offer immediate appeal, the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of these metrics in light of revenue challenges and dividend policy should be closely
monitored. As the healthcare landscape continues to evolve, NRC’s ability to adapt
and innovate will be crucial to enhancing shareholder value and stabilizing its 
market presence.

Share on: